DBV Technologies publie ses résultats financiers annuels 2025 et fait le point sur ses activités

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• DBV is pleased with the progress made in strengthening capabilities and building a company ready for the launch of Viaskin Peanut

  60% confidence

• These estimates are based on the Company's current forecasts and exclude any additional expenses related to programs other than Viaskin Peanut, or resulting from potential licensing or acquisition operations of additional product candidates or technologies

  60% confidence

• The Company may have based these estimates on assumptions that could prove to be inaccurate, and could consequently use its resources more quickly than anticipated

  60% confidence

• Management estimates that the Company has sufficient resources to fund operations through the second quarter of 2027

  60% confidence

• DBV remains firmly committed to making Viaskin Peanut available to children aged 1 to 7 years allergic to peanuts

  60% confidence

• We approached 2025 focused on strengthening the company's financial position, completing the VITESSE study, launching the COMFORT Toddlers study, and preparing for the BLA submission and potential commercial launch in the United States

  60% confidence

Cited in these Via News reports

• Wave Life Sciences Obesity Trial Shows Baseline BMI Gaps Skew Efficacy Data Across Global Drug Race →